Key facts
- This page summarizes Christopher Twitty's Form 4 filing for Skye Bioscience, Inc. (SKYE).
- 12 reported transactions and 12 derivative rows are listed below.
- Accepted by SEC: 02 Apr 2026, 18:21.
Christopher Twitty - 31 Mar 2026 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- SKYE
- Reported as of
- 31 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Apr 2026, 18:21:09 UTC
- Prior SEC filing
- 09 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Punit S. Dhillon, as Attorney-in-Fact for Christopher Twitty
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Twitty filed Form 4 for Skye Bioscience, Inc. (SKYE) on 02 Apr 2026.
Change
- Previous filing in this sequence was filed on 09 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001870121
Primary reporting owner
Twitty Christopher
- Relationship
- Chief Scientific Officer
- Address
- 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
- Signature
- /s/ Punit S. Dhillon, as Attorney-in-Fact for Christopher Twitty
- Signature date
- 02 Apr 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +17,004
- Change %
- Price
- Shares after
- 17,004
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,004
- Exercise price
- $0.6150
- Footnotes
- F1, F2, F3
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -17,004
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,004
- Exercise price
- $3.50
- Footnotes
- F2, F3
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +75,000
- Change %
- Price
- Shares after
- 75,000
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $0.6100
- Footnotes
- F1, F3, F4
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -75,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $14.56
- Footnotes
- F3, F4
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +7,100
- Change %
- Price
- Shares after
- 7,100
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,100
- Exercise price
- $0.6150
- Footnotes
- F1, F3, F5
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -7,100
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,100
- Exercise price
- $3.50
- Footnotes
- F3, F5
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +200,000
- Change %
- Price
- Shares after
- 200,000
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $0.6150
- Footnotes
- F1, F3, F6
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -200,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $5.15
- Footnotes
- F3, F6
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +150,000
- Change %
- Price
- Shares after
- 150,000
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $0.6150
- Footnotes
- F1, F3, F7
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -150,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $2.89
- Footnotes
- F3, F7
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +12,000
- Change %
- Price
- Shares after
- 12,000
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- $0.6150
- Footnotes
- F1, F3, F8
SKYE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -12,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- $4.25
- Footnotes
- F3, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing.
Footnote F2
The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F3
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged.
Footnote F4
The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F5
The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F6
The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.
Footnote F7
The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025. In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025.
Footnote F8
The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.